WATERTOWN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the ...

Congestion, headaches, and sinus infections burden the lives of nearly 30 million Americans suffering from chronic sinusitis each year. For Lizette Serrano, relentless allergies and asthma attacks led ...

Mucoceles are benign sinus tumors that are caused by an obstruction in the sinus ostium. We report 3cases managed at the University Hospital of Kamenge, where treatment was surgical via an endoscopic ...

The reimbursement rates for many ASC procedures have benefited and will benefit under the new Medicare payment system. One such procedure seeing a noticeable reimbursement boost is endoscopy with ...

Please provide your email address to receive an email when new articles are posted on . A 53-year-old female nonsmoker presented to an outpatient facility in November 2017 with 6 weeks of progressive ...

A 49-year-old woman in Nevada developed foreign body (FB) sinusitis after amalgam restorative material moved from a tooth in her upper jaw into the paranasal sinuses. The case report was published ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT ®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U ...

LYR-220, Lyra’s second product candidate, is a long-acting anti-inflammatory therapy in development for CRS patients with and without polyps who have recurrent symptoms despite prior ethmoid sinus ...

Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks Statistically significant improvements in efficacy were observed ...